Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 14, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, March 13, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, March 12, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Debjit Chattopadhyay Maintained (SRPT) at Strong Buy with Increased Target to $92 on, Mar 12th, 2018
Published on 2024-10-26 03:45:01 - WOPRAI, Debjit Chattopadhyay
Debjit Chattopadhyay of HC Wainwright & Co., Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $75 to $92 on, Mar 12th, 2018.
Debjit has made no other calls on SRPT in the last 4 months.
There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 0 agree with Debjit's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Debjit
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $64 on, Tuesday, March 6th, 2018
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $75 on, Wednesday, February 21st, 2018
- Yun Zhong of "Janney Montgomery Scott" Initiated at Strong Buy and Held Target at $75 on, Thursday, January 4th, 2018
